StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd

<< Previous

Bullboard Posts

Next >>

Post by davewhoon Jul 15, 2021 3:42pm

182 Views

Post# 33553668

CBDT

investors not liking their latest results very much.

Total revenues of $2,036,700 for Q1 2021 compared to Q1 2020 revenues $789,135, representing 258% year over year growth.
Loss from operations increased to $1,403,181 for Q1 2021 from $317,831 for Q1 2020, primarily driven by the increased corporate activity of the Company and acquisitions over the prior year which resulted increased costs.
Net loss of $25,213,556 or $0.11 per share compared to $524,208 or $0.00 per share for Q1 2020, which was primarily driven by a non-cash loss on the fair value adjustment related to the Company's warrants outstanding that were impacted by the significant appreciation of the Company's share price (a key input in determining the fair value).
Cash at March 31, 2021 was $6,286,942 which increased from cash of $4,889,824 at December 31, 2020, primarily driven by the proceeds generated on exercise of share purchase warrants.
Cash used in operating activities was $1,422,917, compared to cash provided of $13,864 for Q1 2020.